Logo image of RENB

LUNAI BIOWORKS INC (RENB) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:RENB - US29350E1047 - Common Stock

1.42 USD
+0.15 (+12.16%)
Last: 9/30/2025, 8:00:02 PM
1.54 USD
+0.12 (+8.45%)
After Hours: 9/30/2025, 8:00:02 PM

RENB Key Statistics, Chart & Performance

Key Statistics
Market Cap327.92M
Revenue(TTM)N/A
Net Income(TTM)-67.28M
Shares230.93M
Float146.15M
52 Week High21
52 Week Low1.13
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.44
PEN/A
Fwd PEN/A
Earnings (Next)11-12
IPO2014-11-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
RENB short term performance overview.The bars show the price performance of RENB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

RENB long term performance overview.The bars show the price performance of RENB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RENB is 1.42 USD. In the past month the price decreased by -37.58%. In the past year, price decreased by -70.98%.

LUNAI BIOWORKS INC / RENB Daily stock chart

RENB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RENB Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to RENB. The financial health of RENB is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RENB Financial Highlights

Over the last trailing twelve months RENB reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 59.96% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -57.15%
ROE -76.11%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%100.25%
Sales Q2Q%N/A
EPS 1Y (TTM)59.96%
Revenue 1Y (TTM)N/A

RENB Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

RENB Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

RENB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.65 378.29B
AMGN AMGEN INC 15.13 178.24B
GILD GILEAD SCIENCES INC 15.16 154.02B
VRTX VERTEX PHARMACEUTICALS INC 25.47 112.16B
REGN REGENERON PHARMACEUTICALS 16.3 77.12B
ALNY ALNYLAM PHARMACEUTICALS INC 697.12 46.97B
INSM INSMED INC N/A 34.87B
NTRA NATERA INC N/A 32.41B
BIIB BIOGEN INC 9.88 24.26B
RVMD REVOLUTION MEDICINES INC N/A 22.47B
UTHR UNITED THERAPEUTICS CORP 17.74 20.16B
INCY INCYTE CORP 15.98 20.15B

Related stock screener links

About RENB

Company Profile

RENB logo image Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Company Info

LUNAI BIOWORKS INC

2080 Century Park East, Suite 906

Los Angeles CALIFORNIA US

Employees: 25

RENB Company Website

RENB Investor Relations

Phone: 14539179840

LUNAI BIOWORKS INC / RENB FAQ

What does RENB do?

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 25 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.


Can you provide the latest stock price for LUNAI BIOWORKS INC?

The current stock price of RENB is 1.42 USD. The price increased by 12.16% in the last trading session.


What is the dividend status of LUNAI BIOWORKS INC?

RENB does not pay a dividend.


How is the ChartMill rating for LUNAI BIOWORKS INC?

RENB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


On which exchange is RENB stock listed?

RENB stock is listed on the Nasdaq exchange.